JP2016529292A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016529292A5 JP2016529292A5 JP2016538906A JP2016538906A JP2016529292A5 JP 2016529292 A5 JP2016529292 A5 JP 2016529292A5 JP 2016538906 A JP2016538906 A JP 2016538906A JP 2016538906 A JP2016538906 A JP 2016538906A JP 2016529292 A5 JP2016529292 A5 JP 2016529292A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidine
- diamine
- benzimidazol
- phenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 hydroxyl-amino Chemical group 0.000 claims description 128
- 125000000217 alkyl group Chemical group 0.000 claims description 97
- 150000001875 compounds Chemical class 0.000 claims description 60
- 101100058550 Mus musculus Bmi1 gene Proteins 0.000 claims description 40
- 125000003282 alkyl amino group Chemical group 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 24
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 15
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 230000001404 mediated effect Effects 0.000 claims description 12
- 210000000130 stem cell Anatomy 0.000 claims description 12
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 6
- 239000013522 chelant Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- UVHMUJSQWRYWDU-UHFFFAOYSA-N Cl.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cl.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 UVHMUJSQWRYWDU-UHFFFAOYSA-N 0.000 claims description 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 4
- 102000004243 Tubulin Human genes 0.000 claims description 4
- 108090000704 Tubulin Proteins 0.000 claims description 4
- 239000003470 adrenal cortex hormone Substances 0.000 claims description 4
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 239000003430 antimalarial agent Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 125000001769 aryl amino group Chemical group 0.000 claims description 4
- 229940124748 beta 2 agonist Drugs 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000003124 biologic agent Substances 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 239000000812 cholinergic antagonist Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000003862 glucocorticoid Substances 0.000 claims description 4
- 229940125697 hormonal agent Drugs 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 230000002584 immunomodulator Effects 0.000 claims description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 239000008177 pharmaceutical agent Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- ZQXSKIOXBAHJFB-UHFFFAOYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-6-(2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC=1C=C(C=CC=1C(F)(F)F)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N ZQXSKIOXBAHJFB-UHFFFAOYSA-N 0.000 claims description 2
- GEFKLPJLQJIZIK-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-3-fluorophenyl]-6-(2-ethyl-6-fluorobenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=C(C=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)N)F)F GEFKLPJLQJIZIK-UHFFFAOYSA-N 0.000 claims description 2
- FTLIXSOLZZNVIS-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-3-fluorophenyl]-6-(2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=C(C=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N)F)F FTLIXSOLZZNVIS-UHFFFAOYSA-N 0.000 claims description 2
- ULAPUNCOGWESBX-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-3-fluorophenyl]-6-(5-fluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=C(C=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC(=C2)F)C)N)F)F ULAPUNCOGWESBX-UHFFFAOYSA-N 0.000 claims description 2
- JVBZMYGXBPXIRT-UHFFFAOYSA-N 2-[4-(difluoromethoxy)-3-fluorophenyl]-6-(6-fluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=C(C=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C)N)F)F JVBZMYGXBPXIRT-UHFFFAOYSA-N 0.000 claims description 2
- JUCJUKGQBOPFBZ-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-5-fluoro-6-(2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=C(C(=N1)N)F)N1C(=NC2=C1C=CC=C2)C)N)F JUCJUKGQBOPFBZ-UHFFFAOYSA-N 0.000 claims description 2
- IALBUPOOHQBYQP-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(2,5,6-trimethylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine 6-(3,5-dimethyl-1,2-oxazol-4-yl)-2-N-(4-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound CC1=NOC(=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC)N)C.FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)C)C)C)N)F IALBUPOOHQBYQP-UHFFFAOYSA-N 0.000 claims description 2
- PMWSONWBUJYXIA-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(2,6-dimethylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)C)C)N)F PMWSONWBUJYXIA-UHFFFAOYSA-N 0.000 claims description 2
- JJUBGPRIAWLNSG-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(2-ethyl-6-fluorobenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)N)F JJUBGPRIAWLNSG-UHFFFAOYSA-N 0.000 claims description 2
- XNXCLICHUIPSLU-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(2-propan-2-ylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C(C)C)N)F XNXCLICHUIPSLU-UHFFFAOYSA-N 0.000 claims description 2
- PBLUFQAQWINLBU-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(4,6-difluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2F)F)C)N)F PBLUFQAQWINLBU-UHFFFAOYSA-N 0.000 claims description 2
- HSGWNSAGTGJEJS-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(4-fluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2F)C)N)F HSGWNSAGTGJEJS-UHFFFAOYSA-N 0.000 claims description 2
- XQUSLGVVYKQHCP-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(5,6-difluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)F)F)C)N)F XQUSLGVVYKQHCP-UHFFFAOYSA-N 0.000 claims description 2
- KVUUOHXNBZDTBU-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(5,7-difluoro-2-methylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C(=CC(=C2)F)F)C)N)F KVUUOHXNBZDTBU-UHFFFAOYSA-N 0.000 claims description 2
- BAKNKXJUSSAYMT-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(5-fluoro-2-propan-2-ylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC(=C2)F)C(C)C)N)F BAKNKXJUSSAYMT-UHFFFAOYSA-N 0.000 claims description 2
- ZOEZVBZFTKJNEE-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-(6-fluoro-2-propan-2-ylbenzimidazol-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C(C)C)N)F ZOEZVBZFTKJNEE-UHFFFAOYSA-N 0.000 claims description 2
- VVVGUDDIVWGFNM-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-[2-(difluoromethyl)-6-fluorobenzimidazol-1-yl]-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C(F)F)N)F VVVGUDDIVWGFNM-UHFFFAOYSA-N 0.000 claims description 2
- SHHZOXQIHCKAAN-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-[2-(difluoromethyl)benzimidazol-1-yl]-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C(F)F)N)F SHHZOXQIHCKAAN-UHFFFAOYSA-N 0.000 claims description 2
- JBUUKDJZTHOULF-UHFFFAOYSA-N 2-[4-(difluoromethoxy)phenyl]-6-[6-fluoro-2-(methoxymethyl)benzimidazol-1-yl]-1H-pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)COC)N)F JBUUKDJZTHOULF-UHFFFAOYSA-N 0.000 claims description 2
- NPGWDGRCAMIOMW-UHFFFAOYSA-N 4-(6-chloro-2-methylbenzimidazol-1-yl)-2-[4-(trifluoromethyl)anilino]-1H-pyrimidin-6-one Chemical compound ClC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)O)C=1 NPGWDGRCAMIOMW-UHFFFAOYSA-N 0.000 claims description 2
- GSIOXNJEAZAZJI-UHFFFAOYSA-N 5-fluoro-6-(2-methylbenzimidazol-1-yl)-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound Cc1nc2ccccc2n1-c1nc(Nc2ccc(cc2)C(F)(F)F)nc(N)c1F GSIOXNJEAZAZJI-UHFFFAOYSA-N 0.000 claims description 2
- VHGCPAWEEVYUGT-UHFFFAOYSA-N 6-(2-ethylbenzimidazol-1-yl)-5-fluoro-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound CCc1nc2ccccc2n1-c1nc(Nc2ccc(cc2)C(F)(F)F)nc(N)c1F VHGCPAWEEVYUGT-UHFFFAOYSA-N 0.000 claims description 2
- BGRHQELBROFBDH-UHFFFAOYSA-N 6-(4-fluoro-2-methylbenzimidazol-1-yl)-2-N-[3-methyl-4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound FC1=CC=CC=2N(C(=NC=21)C)C1=CC(=NC(=N1)NC1=CC(=C(C=C1)C(F)(F)F)C)N BGRHQELBROFBDH-UHFFFAOYSA-N 0.000 claims description 2
- DCDIAVGFVYOHKM-UHFFFAOYSA-N 6-(5-chloro-2-cyclopropylbenzimidazol-1-yl)-2-N-[4-(difluoromethoxy)phenyl]pyrimidine-2,4-diamine Chemical compound ClC1=CC2=C(N(C(=N2)C2CC2)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC(F)F)N)C=C1 DCDIAVGFVYOHKM-UHFFFAOYSA-N 0.000 claims description 2
- MUUNVQIOYJNBBB-UHFFFAOYSA-N 6-(5-chloro-2-cyclopropylbenzimidazol-1-yl)-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound ClC1=CC2=C(N(C(=N2)C2CC2)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=C1 MUUNVQIOYJNBBB-UHFFFAOYSA-N 0.000 claims description 2
- BHHSOANUXVIOGN-UHFFFAOYSA-N 6-(6-chloro-2-cyclopropylbenzimidazol-1-yl)-2-N-[4-(difluoromethoxy)phenyl]pyrimidine-2,4-diamine Chemical compound ClC=1C=CC2=C(N(C(=N2)C2CC2)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC(F)F)N)C=1 BHHSOANUXVIOGN-UHFFFAOYSA-N 0.000 claims description 2
- NJXICRJXDBDCMY-UHFFFAOYSA-N 6-[2-(methoxymethyl)benzimidazol-1-yl]-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound COCc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 NJXICRJXDBDCMY-UHFFFAOYSA-N 0.000 claims description 2
- GPVJKNAZBWNDCK-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=C(C(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)F)C=C(C=C2)F Chemical compound C(C)C1=NC2=C(N1C1=C(C(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)F)C=C(C=C2)F GPVJKNAZBWNDCK-UHFFFAOYSA-N 0.000 claims description 2
- RYIZSNJRUYFDTF-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F RYIZSNJRUYFDTF-UHFFFAOYSA-N 0.000 claims description 2
- PBALYBIEHQTFLY-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC(=C2)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC(=C2)F PBALYBIEHQTFLY-UHFFFAOYSA-N 0.000 claims description 2
- FPDFLYXTKOWKAH-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC=1C=NC(=CC1)C(F)(F)F)N)C=C(C=C2)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC=1C=NC(=CC1)C(F)(F)F)N)C=C(C=C2)F FPDFLYXTKOWKAH-UHFFFAOYSA-N 0.000 claims description 2
- ZVSNKRCYLIIUQO-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC=1C=NC(=CC1)C(F)(F)F)N)C=CC(=C2)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC=1C=NC(=CC1)C(F)(F)F)N)C=CC(=C2)F ZVSNKRCYLIIUQO-UHFFFAOYSA-N 0.000 claims description 2
- ZXEJIVNVZNAEKO-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=[N+](C(=N1)NC1=CC=C(C=C1)C(F)(F)F)[O-])N)C=CC=C2 Chemical compound C(C)C1=NC2=C(N1C1=CC(=[N+](C(=N1)NC1=CC=C(C=C1)C(F)(F)F)[O-])N)C=CC=C2 ZXEJIVNVZNAEKO-UHFFFAOYSA-N 0.000 claims description 2
- WKXHYUMRBOVWCF-UHFFFAOYSA-N C(C)C1=NN2C(C=C(C=C2)F)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound C(C)C1=NN2C(C=C(C=C2)F)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N WKXHYUMRBOVWCF-UHFFFAOYSA-N 0.000 claims description 2
- JAAAOQDXIYGCOT-UHFFFAOYSA-N C(C)C1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound C(C)C1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N JAAAOQDXIYGCOT-UHFFFAOYSA-N 0.000 claims description 2
- PFTWICZZYOGGCM-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC(F)F)F)N)C=C(C=C2)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC(F)F)F)N)C=C(C=C2)F PFTWICZZYOGGCM-UHFFFAOYSA-N 0.000 claims description 2
- QNRDNFFQKNHDSS-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)C#N)C=C(C(=C2)F)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)C#N)C=C(C(=C2)F)F QNRDNFFQKNHDSS-UHFFFAOYSA-N 0.000 claims description 2
- LKXBUDLEPFZVQB-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F LKXBUDLEPFZVQB-UHFFFAOYSA-N 0.000 claims description 2
- DQUCIBDXZZUKHO-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC(=C2)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC(=C2)F DQUCIBDXZZUKHO-UHFFFAOYSA-N 0.000 claims description 2
- PLUDRSNUTJFLSG-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=C(C(=C2)F)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=C(C(=C2)F)F PLUDRSNUTJFLSG-UHFFFAOYSA-N 0.000 claims description 2
- QLBZXFLABKMREJ-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=C(C=C2)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=C(C=C2)F QLBZXFLABKMREJ-UHFFFAOYSA-N 0.000 claims description 2
- ULKOCOFOEXRHRA-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=CC(=C2)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=CC(=C2)F ULKOCOFOEXRHRA-UHFFFAOYSA-N 0.000 claims description 2
- YRFJLNMAMIMQSD-UHFFFAOYSA-N C1(CC1)C1=NN2C(C=C(C=C2)OC)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound C1(CC1)C1=NN2C(C=C(C=C2)OC)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N YRFJLNMAMIMQSD-UHFFFAOYSA-N 0.000 claims description 2
- RHTRJYZJUQCTMR-UHFFFAOYSA-N C1(CC1)C=1N=C2N(C=C(C=C2)F)C=1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC(F)F)F)N Chemical compound C1(CC1)C=1N=C2N(C=C(C=C2)F)C=1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC(F)F)F)N RHTRJYZJUQCTMR-UHFFFAOYSA-N 0.000 claims description 2
- UYXIRFZDQFFGTI-UHFFFAOYSA-N CC(C)c1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CC(C)c1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 UYXIRFZDQFFGTI-UHFFFAOYSA-N 0.000 claims description 2
- XPQNXSXRGQWHJB-UHFFFAOYSA-N CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)C(F)(F)F)C)N)C=C(C=C2)C Chemical compound CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)C(F)(F)F)C)N)C=C(C=C2)C XPQNXSXRGQWHJB-UHFFFAOYSA-N 0.000 claims description 2
- VOQDFHNAPBZRID-UHFFFAOYSA-N CC1=NC2=C(N1C1=CC(=[N+](C(=N1)NC1=CC=C(C=C1)C(F)(F)F)[O-])N)C=CC=C2 Chemical compound CC1=NC2=C(N1C1=CC(=[N+](C(=N1)NC1=CC=C(C=C1)C(F)(F)F)[O-])N)C=CC=C2 VOQDFHNAPBZRID-UHFFFAOYSA-N 0.000 claims description 2
- SQLNFUWRPVHUJV-UHFFFAOYSA-N CCc1nc2cc(F)c(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CCc1nc2cc(F)c(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 SQLNFUWRPVHUJV-UHFFFAOYSA-N 0.000 claims description 2
- CVBKBJKUGDYLOB-UHFFFAOYSA-N CCc1nc2ccc(F)cc2n1-c1cc(N)[n+]([O-])c(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CCc1nc2ccc(F)cc2n1-c1cc(N)[n+]([O-])c(Nc2ccc(cc2)C(F)(F)F)n1 CVBKBJKUGDYLOB-UHFFFAOYSA-N 0.000 claims description 2
- UKKWKYFJRBRRIR-UHFFFAOYSA-N COC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C Chemical compound COC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C UKKWKYFJRBRRIR-UHFFFAOYSA-N 0.000 claims description 2
- FHJVMKSUWXTSQN-UHFFFAOYSA-N COC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)C)C)C.ClC2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C(=C1)C)C)C)N Chemical compound COC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)C)C)C.ClC2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C(=C1)C)C)C)N FHJVMKSUWXTSQN-UHFFFAOYSA-N 0.000 claims description 2
- APVNWTYMKFWTSV-UHFFFAOYSA-N COc1ccn2nc(C)c(-c3cc(Cl)nc(Nc4ccc(cc4)C(F)(F)F)n3)c2c1 Chemical compound COc1ccn2nc(C)c(-c3cc(Cl)nc(Nc4ccc(cc4)C(F)(F)F)n3)c2c1 APVNWTYMKFWTSV-UHFFFAOYSA-N 0.000 claims description 2
- OBBVCAZVYACJLE-UHFFFAOYSA-N CS(O)(=O)=O.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CS(O)(=O)=O.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 OBBVCAZVYACJLE-UHFFFAOYSA-N 0.000 claims description 2
- VGVNUIACCQWQTL-UHFFFAOYSA-N CSc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CSc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 VGVNUIACCQWQTL-UHFFFAOYSA-N 0.000 claims description 2
- ARZKGHFASKMVAO-UHFFFAOYSA-N Cc1nc2cc(F)c(F)cc2n1-c1cc(Cl)nc(Nc2ccc(c(F)c2)C(F)(F)F)n1 Chemical compound Cc1nc2cc(F)c(F)cc2n1-c1cc(Cl)nc(Nc2ccc(c(F)c2)C(F)(F)F)n1 ARZKGHFASKMVAO-UHFFFAOYSA-N 0.000 claims description 2
- HMWCYDKGUORIJO-UHFFFAOYSA-N Cc1nc2cc(F)c(F)cc2n1-c1cc(Cl)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2cc(F)c(F)cc2n1-c1cc(Cl)nc(Nc2ccc(cc2)C(F)(F)F)n1 HMWCYDKGUORIJO-UHFFFAOYSA-N 0.000 claims description 2
- XEDSCUFFFKQSSF-UHFFFAOYSA-N Cc1nc2cc(F)c(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2cc(F)c(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 XEDSCUFFFKQSSF-UHFFFAOYSA-N 0.000 claims description 2
- OYVPSYAAYYNXJB-UHFFFAOYSA-N Cc1nc2cc(F)c(F)cc2n1-c1cc(NCCO)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2cc(F)c(F)cc2n1-c1cc(NCCO)nc(Nc2ccc(cc2)C(F)(F)F)n1 OYVPSYAAYYNXJB-UHFFFAOYSA-N 0.000 claims description 2
- WSFRTACIEUQPIZ-UHFFFAOYSA-N Cc1nc2ccc(Br)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccc(Br)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 WSFRTACIEUQPIZ-UHFFFAOYSA-N 0.000 claims description 2
- ZBKWLOOWZLVJTR-UHFFFAOYSA-N Cc1nc2ccc(C)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccc(C)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 ZBKWLOOWZLVJTR-UHFFFAOYSA-N 0.000 claims description 2
- AENNVTBAVGDKDP-UHFFFAOYSA-N Cc1nc2ccc(Cl)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccc(Cl)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 AENNVTBAVGDKDP-UHFFFAOYSA-N 0.000 claims description 2
- PJXNRAKFPGWJEQ-UHFFFAOYSA-N Cc1nc2ccc(F)cc2n1-c1cc(Cl)nc(Nc2ccc(nc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccc(F)cc2n1-c1cc(Cl)nc(Nc2ccc(nc2)C(F)(F)F)n1 PJXNRAKFPGWJEQ-UHFFFAOYSA-N 0.000 claims description 2
- ZIVCGQXXZOYBEB-UHFFFAOYSA-N Cc1nc2ccc(F)cc2n1-c1cc(N)[n+]([O-])c(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccc(F)cc2n1-c1cc(N)[n+]([O-])c(Nc2ccc(cc2)C(F)(F)F)n1 ZIVCGQXXZOYBEB-UHFFFAOYSA-N 0.000 claims description 2
- JZEJKINDEPHXFP-UHFFFAOYSA-N Cc1nc2ccc(F)cc2n1-c1nc(Nc2ccc(cc2)C(F)(F)F)nc(N)c1F Chemical compound Cc1nc2ccc(F)cc2n1-c1nc(Nc2ccc(cc2)C(F)(F)F)nc(N)c1F JZEJKINDEPHXFP-UHFFFAOYSA-N 0.000 claims description 2
- NPPXWLMECFRCOJ-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(OC(F)F)c(F)c2)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(OC(F)F)c(F)c2)n1 NPPXWLMECFRCOJ-UHFFFAOYSA-N 0.000 claims description 2
- LAHZJQOPRFACRR-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(nc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(nc2)C(F)(F)F)n1 LAHZJQOPRFACRR-UHFFFAOYSA-N 0.000 claims description 2
- PYXZCNOEZVBDDA-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(nc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(nc2)C(F)(F)F)n1 PYXZCNOEZVBDDA-UHFFFAOYSA-N 0.000 claims description 2
- BGWSBNYTRRRNHH-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(NCCO)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(NCCO)nc(Nc2ccc(cc2)C(F)(F)F)n1 BGWSBNYTRRRNHH-UHFFFAOYSA-N 0.000 claims description 2
- PSXUKEYJGCELRP-UHFFFAOYSA-N Cc1nn2ccc(N)cc2c1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nn2ccc(N)cc2c1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 PSXUKEYJGCELRP-UHFFFAOYSA-N 0.000 claims description 2
- RBLAETGMQKJETF-UHFFFAOYSA-N ClC1=C(C=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)F.ClC2=C(C=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N)F Chemical compound ClC1=C(C=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)F.ClC2=C(C=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N)F RBLAETGMQKJETF-UHFFFAOYSA-N 0.000 claims description 2
- AYMQISSGOMNESH-UHFFFAOYSA-N ClC1=C(C=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)F.FC=2C(=NC(=NC2N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C=C1)C)N Chemical compound ClC1=C(C=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)F.FC=2C(=NC(=NC2N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C=C1)C)N AYMQISSGOMNESH-UHFFFAOYSA-N 0.000 claims description 2
- UDODHYSSEXCMAX-UHFFFAOYSA-N ClC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=C1 Chemical compound ClC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=C1 UDODHYSSEXCMAX-UHFFFAOYSA-N 0.000 claims description 2
- SOIMCHIAIBRSJC-UHFFFAOYSA-N ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C Chemical compound ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C SOIMCHIAIBRSJC-UHFFFAOYSA-N 0.000 claims description 2
- RKCWWSQYFVHWKI-UHFFFAOYSA-N ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)CC Chemical compound ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)CC RKCWWSQYFVHWKI-UHFFFAOYSA-N 0.000 claims description 2
- AOAKWCGAWDLNEB-UHFFFAOYSA-N ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C Chemical compound ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C AOAKWCGAWDLNEB-UHFFFAOYSA-N 0.000 claims description 2
- DOFDYOBLCJHYIC-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)C=1C(=NOC1C)C Chemical compound ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)C=1C(=NOC1C)C DOFDYOBLCJHYIC-UHFFFAOYSA-N 0.000 claims description 2
- WQFWJOGHOJHFRF-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.FC=2C(=NC(=NC2N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C=C1)OC)N Chemical compound ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.FC=2C(=NC(=NC2N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C=C1)OC)N WQFWJOGHOJHFRF-UHFFFAOYSA-N 0.000 claims description 2
- CVAIQLRVHAJYLK-UHFFFAOYSA-N ClC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)C)C)C.FC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C(=C1)C)C)C)N Chemical compound ClC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C(=C2)C)C)C.FC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C(=C1)C)C)C)N CVAIQLRVHAJYLK-UHFFFAOYSA-N 0.000 claims description 2
- LIRWGVDWUMNQKS-UHFFFAOYSA-N ClC=1C=C2C(=NC1)N=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C Chemical compound ClC=1C=C2C(=NC1)N=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C LIRWGVDWUMNQKS-UHFFFAOYSA-N 0.000 claims description 2
- FXYGBAWVXMCAJD-UHFFFAOYSA-N ClC=1C=CC2=C(N(C(=N2)C2CC2)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=1 Chemical compound ClC=1C=CC2=C(N(C(=N2)C2CC2)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=1 FXYGBAWVXMCAJD-UHFFFAOYSA-N 0.000 claims description 2
- CLBGUSRZWVQBNE-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC=C2)F Chemical compound FC(C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=CC=C2)F CLBGUSRZWVQBNE-UHFFFAOYSA-N 0.000 claims description 2
- MEHKAFRKXGGFDN-UHFFFAOYSA-N FC(OC1=C(C=C(C=C1)NC1=NC(=CC(=N1)NCCO)N1C(=NC2=C1C=CC=C2)C)F)F Chemical compound FC(OC1=C(C=C(C=C1)NC1=NC(=CC(=N1)NCCO)N1C(=NC2=C1C=CC=C2)C)F)F MEHKAFRKXGGFDN-UHFFFAOYSA-N 0.000 claims description 2
- YIXJRKKDLCAKPE-UHFFFAOYSA-N FC1=CC(=CC=2N(C(=NC=21)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)F Chemical compound FC1=CC(=CC=2N(C(=NC=21)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)F YIXJRKKDLCAKPE-UHFFFAOYSA-N 0.000 claims description 2
- CSPGXXIOHYEDNJ-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)C#N)C=C1F Chemical compound FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)C#N)C=C1F CSPGXXIOHYEDNJ-UHFFFAOYSA-N 0.000 claims description 2
- HHKSIMCGRBYYQH-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=C1 Chemical compound FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C=C1 HHKSIMCGRBYYQH-UHFFFAOYSA-N 0.000 claims description 2
- OQOUSQVVDXVHTL-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N)C=C1F.FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=C1F Chemical compound FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N)C=C1F.FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=C1F OQOUSQVVDXVHTL-UHFFFAOYSA-N 0.000 claims description 2
- ZJKRRPIHILSEQU-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC=2C=NC(=CC2)C(F)(F)F)N)C=C1 Chemical compound FC1=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC=2C=NC(=CC2)C(F)(F)F)N)C=C1 ZJKRRPIHILSEQU-UHFFFAOYSA-N 0.000 claims description 2
- AAQXADZWUAJCPX-UHFFFAOYSA-N FC1=CC=CC=2N(C(=NC=21)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound FC1=CC=CC=2N(C(=NC=21)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N AAQXADZWUAJCPX-UHFFFAOYSA-N 0.000 claims description 2
- WMGZXENSYVQXKK-UHFFFAOYSA-N FC=1C(=NC(=NC=1N1C(=NC2=NC=CC=C21)C)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound FC=1C(=NC(=NC=1N1C(=NC2=NC=CC=C21)C)NC1=CC=C(C=C1)C(F)(F)F)N WMGZXENSYVQXKK-UHFFFAOYSA-N 0.000 claims description 2
- LJKBYYFIXOCHFR-UHFFFAOYSA-N FC=1C=C(C=CC1C(F)(F)F)NC1=NC(=CC(=N1)NCCO)N1C(=NC2=C1C=CC=C2)C Chemical compound FC=1C=C(C=CC1C(F)(F)F)NC1=NC(=CC(=N1)NCCO)N1C(=NC2=C1C=CC=C2)C LJKBYYFIXOCHFR-UHFFFAOYSA-N 0.000 claims description 2
- HJLPKQFBAPTGDX-UHFFFAOYSA-N FC=1C=C2C(=NC1)N=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C Chemical compound FC=1C=C2C(=NC1)N=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C HJLPKQFBAPTGDX-UHFFFAOYSA-N 0.000 claims description 2
- WQENDOFRRFUMMV-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)NP(O)(O)=O)C1 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)NP(O)(O)=O)C1 WQENDOFRRFUMMV-UHFFFAOYSA-N 0.000 claims description 2
- TZKNARDNLYFEKK-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC=2C=NC(=CC2)C(F)(F)F)N)C1 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC=2C=NC(=CC2)C(F)(F)F)N)C1 TZKNARDNLYFEKK-UHFFFAOYSA-N 0.000 claims description 2
- FBKKZISPUBVRGI-UHFFFAOYSA-N FC=1C=CC=2N(C=1)C(=C(N=2)C(F)(F)F)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound FC=1C=CC=2N(C=1)C(=C(N=2)C(F)(F)F)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N FBKKZISPUBVRGI-UHFFFAOYSA-N 0.000 claims description 2
- LSTUXSHUKCOXIG-UHFFFAOYSA-N FC=1C=CC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound FC=1C=CC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N LSTUXSHUKCOXIG-UHFFFAOYSA-N 0.000 claims description 2
- XGIVNHWUQZKCMC-UHFFFAOYSA-N FC=1C=NC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound FC=1C=NC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N XGIVNHWUQZKCMC-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- HYUVZQNLPOASLR-UHFFFAOYSA-N NC(=O)c1cccc(Nc2nccc(n2)-c2cnc3ccccn23)c1 Chemical compound NC(=O)c1cccc(Nc2nccc(n2)-c2cnc3ccccn23)c1 HYUVZQNLPOASLR-UHFFFAOYSA-N 0.000 claims description 2
- QADNNUXKJSZDGS-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(CO)nc2ccc(F)cn12 Chemical compound Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(CO)nc2ccc(F)cn12 QADNNUXKJSZDGS-UHFFFAOYSA-N 0.000 claims description 2
- JMOMFGKMJUNDFC-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(CO)nc2ccccn12 Chemical compound Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(CO)nc2ccccn12 JMOMFGKMJUNDFC-UHFFFAOYSA-N 0.000 claims description 2
- BHLVPZQSVLWONV-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(nn2ccc(F)cc12)C1CC1 Chemical compound Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(nn2ccc(F)cc12)C1CC1 BHLVPZQSVLWONV-UHFFFAOYSA-N 0.000 claims description 2
- BKYCJXKBHUIZJJ-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-n1c(nc2ccccc12)C1CC1 Chemical compound Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-n1c(nc2ccccc12)C1CC1 BKYCJXKBHUIZJJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004949 alkyl amino carbonyl amino group Chemical group 0.000 claims description 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 6
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 229940033495 antimalarials Drugs 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 229940037128 systemic glucocorticoids Drugs 0.000 claims 2
- INFUUVWCISPPNA-UHFFFAOYSA-N 2-N-[4-(difluoromethoxy)phenyl]-6-(2-methylbenzimidazol-1-yl)pyrimidine-2,4-diamine 6-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound FC(OC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)F.CC2=NN1C(C=CC=C1)=C2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N INFUUVWCISPPNA-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- UFSZGTGHGMGGSH-UHFFFAOYSA-N BrC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.O2COC1=C2C=CC(=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N Chemical compound BrC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.O2COC1=C2C=CC(=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N UFSZGTGHGMGGSH-UHFFFAOYSA-N 0.000 claims 1
- QOGLPHIKVXIBKU-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N)C=C(C=C1)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N)C=C(C=C1)F QOGLPHIKVXIBKU-UHFFFAOYSA-N 0.000 claims 1
- YBTBKZLJUJMCIX-UHFFFAOYSA-N C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=CC=C2.FC(OC2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC)N)F Chemical compound C1(CC1)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)C=CC=C2.FC(OC2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC)N)F YBTBKZLJUJMCIX-UHFFFAOYSA-N 0.000 claims 1
- DADRCXIDDPXQRX-UHFFFAOYSA-N C1(CC1)C1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound C1(CC1)C1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N DADRCXIDDPXQRX-UHFFFAOYSA-N 0.000 claims 1
- IKQWMMFCFZNLEH-UHFFFAOYSA-N CCc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(nc2)C(F)(F)F)n1 Chemical compound CCc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(nc2)C(F)(F)F)n1 IKQWMMFCFZNLEH-UHFFFAOYSA-N 0.000 claims 1
- OUSLIALZQGMFDW-UHFFFAOYSA-N COC1=CC=C(C=N1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.ClC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC)N Chemical compound COC1=CC=C(C=N1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.ClC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC)N OUSLIALZQGMFDW-UHFFFAOYSA-N 0.000 claims 1
- NZYRMTPVDDPXAC-UHFFFAOYSA-N ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)CC Chemical compound ClC1=CC=2N(C=C1)N=C(C=2C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)F)N)CC NZYRMTPVDDPXAC-UHFFFAOYSA-N 0.000 claims 1
- VEWPFHCGNXBHAP-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C2 Chemical compound ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C2 VEWPFHCGNXBHAP-UHFFFAOYSA-N 0.000 claims 1
- XZIACQKIZZGHJP-UHFFFAOYSA-N ClC=1C=C(C=CC1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC(=CC=C1)OC)N)C2 Chemical compound ClC=1C=C(C=CC1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC(=CC=C1)OC)N)C2 XZIACQKIZZGHJP-UHFFFAOYSA-N 0.000 claims 1
- SSSNCIHDYXBIRJ-UHFFFAOYSA-N FC1=CC2=C(N(C(=N2)C)C2=CC(=[N+](C(=N2)NC2=CC=C(C=C2)C(F)(F)F)[O-])N)C=C1 Chemical compound FC1=CC2=C(N(C(=N2)C)C2=CC(=[N+](C(=N2)NC2=CC=C(C=C2)C(F)(F)F)[O-])N)C=C1 SSSNCIHDYXBIRJ-UHFFFAOYSA-N 0.000 claims 1
- IGXCYZGPQAPEHX-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C1.FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)F)N)C1 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C1.FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)F)N)C1 IGXCYZGPQAPEHX-UHFFFAOYSA-N 0.000 claims 1
- MPHYLSDYEDPUAV-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C1.CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)[N+](=O)[O-])N)C=CC=C2 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C1.CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)[N+](=O)[O-])N)C=CC=C2 MPHYLSDYEDPUAV-UHFFFAOYSA-N 0.000 claims 1
- QGSGCWXBDZXIPK-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=CC=C2)N)C1.FC=1C=C(C=CC1OC)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C)N Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=CC=C2)N)C1.FC=1C=C(C=CC1OC)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C)N QGSGCWXBDZXIPK-UHFFFAOYSA-N 0.000 claims 1
- VZIQLYXQPKSWFF-UHFFFAOYSA-N FC=1C=CC=2N(C1)C(=C(N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N.FC=2C=CC=1N(C2)C(=C(N1)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC)N Chemical compound FC=1C=CC=2N(C1)C(=C(N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C)N.FC=2C=CC=1N(C2)C(=C(N1)C)C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC)N VZIQLYXQPKSWFF-UHFFFAOYSA-N 0.000 claims 1
- PHJXDQCLLHFNNY-UHFFFAOYSA-N FC=1C=CC=2N(C1)C(=C(N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)F)N.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=C(C=C2)OC)F)N)C=C(C=C1)F Chemical compound FC=1C=CC=2N(C1)C(=C(N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)F)N.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=C(C=C2)OC)F)N)C=C(C=C1)F PHJXDQCLLHFNNY-UHFFFAOYSA-N 0.000 claims 1
- DPEFEGBKGAQPQB-UHFFFAOYSA-N NC1=NC(=NC(=C1)N1C(=NC2=C1C=C(C=C2)F)C)NC2=CC=C(C#N)C=C2.CN(C2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N)C Chemical compound NC1=NC(=NC(=C1)N1C(=NC2=C1C=C(C=C2)F)C)NC2=CC=C(C#N)C=C2.CN(C2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N)C DPEFEGBKGAQPQB-UHFFFAOYSA-N 0.000 claims 1
- UNXGYEMTUPIWPM-UHFFFAOYSA-N NC1=NC(=NC(=C1)N1C(=NC2=C1C=CC=C2)C)NC2=CC=C(C#N)C=C2.CN(C2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N)C Chemical compound NC1=NC(=NC(=C1)N1C(=NC2=C1C=CC=C2)C)NC2=CC=C(C#N)C=C2.CN(C2=CC=C(C=C2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N)C UNXGYEMTUPIWPM-UHFFFAOYSA-N 0.000 claims 1
- FZFHEKHZUZTEPT-UHFFFAOYSA-N NC1=NC(NC2=CC=C(C(F)(F)F)C=C2)=NC=C1N1C(C=C(C(F)=C2)F)=C2N=C1C1CC1 Chemical compound NC1=NC(NC2=CC=C(C(F)(F)F)C=C2)=NC=C1N1C(C=C(C(F)=C2)F)=C2N=C1C1CC1 FZFHEKHZUZTEPT-UHFFFAOYSA-N 0.000 claims 1
- WWQISFGKKBABKK-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(nc2ccc(F)cn12)C(F)F Chemical compound Nc1cc(nc(Nc2ccc(cc2)C(F)(F)F)n1)-c1c(nc2ccc(F)cn12)C(F)F WWQISFGKKBABKK-UHFFFAOYSA-N 0.000 claims 1
- 125000000676 alkoxyimino group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NPRASAIVKHLQCJ-UHFFFAOYSA-N Br.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Br.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 NPRASAIVKHLQCJ-UHFFFAOYSA-N 0.000 description 1
- KLNJRGZYRPLXGV-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=C(C=CC=C1)C)N)C=CC=C2.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=CC=C1 Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=C(C=CC=C1)C)N)C=CC=C2.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=CC=C1 KLNJRGZYRPLXGV-UHFFFAOYSA-N 0.000 description 1
- NGUDGFDCKDYCGG-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC)F)N)C=C(C=C2)F.NC2=NC(=NC(=C2)N2C(=NC1=C2C=C(C=C1)F)CC)NC1=CC=C(C#N)C=C1 Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=C(C=C1)OC)F)N)C=C(C=C2)F.NC2=NC(=NC(=C2)N2C(=NC1=C2C=C(C=C1)F)CC)NC1=CC=C(C#N)C=C1 NGUDGFDCKDYCGG-UHFFFAOYSA-N 0.000 description 1
- IMLHOFPXDKRHGG-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=CC=C1)C)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=CC=C2)OC)N)C=C(C=C1)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC(=CC=C1)C)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=CC=C2)OC)N)C=C(C=C1)F IMLHOFPXDKRHGG-UHFFFAOYSA-N 0.000 description 1
- HWQRKHHVNSCPEF-UHFFFAOYSA-N C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=CC=C2)N)C=C(C=C1)F Chemical compound C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=C(C=C2)F.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=CC=C2)N)C=C(C=C1)F HWQRKHHVNSCPEF-UHFFFAOYSA-N 0.000 description 1
- GKSQFGOQBMXDTN-UHFFFAOYSA-N CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=CC=C2.CC2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C=CC=C1 Chemical compound CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=CC=C2.CC2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C=CC=C1 GKSQFGOQBMXDTN-UHFFFAOYSA-N 0.000 description 1
- HGPIUVZQJKRRQT-UHFFFAOYSA-N CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)(F)F)N)C=CC=C2.NC2=NC(=NC(=C2)N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C#N)C=C1 Chemical compound CC1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)OC(F)(F)F)N)C=CC=C2.NC2=NC(=NC(=C2)N2C(=NC1=C2C=CC=C1)C)NC1=CC=C(C#N)C=C1 HGPIUVZQJKRRQT-UHFFFAOYSA-N 0.000 description 1
- LXNLGFCGQJCOJW-UHFFFAOYSA-N CC1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N Chemical compound CC1=NN2C(C=CC=C2)=C1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N LXNLGFCGQJCOJW-UHFFFAOYSA-N 0.000 description 1
- VKXXZUHNZWXELK-UHFFFAOYSA-N CCc1nc2ccc(Cl)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CCc1nc2ccc(Cl)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 VKXXZUHNZWXELK-UHFFFAOYSA-N 0.000 description 1
- COXWZZJELSWXBH-UHFFFAOYSA-N CN(C1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)C.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=C(C=C1)F Chemical compound CN(C1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC)C.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC=C(C=C2)OC)N)C=C(C=C1)F COXWZZJELSWXBH-UHFFFAOYSA-N 0.000 description 1
- FDSZICSXKZKJBR-UHFFFAOYSA-N CN(C1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC=CC=C1)N)C2 Chemical compound CN(C1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)C.FC=2C=CC1=C(N(C(=N1)C)C1=CC(=NC(=N1)NC1=CC=CC=C1)N)C2 FDSZICSXKZKJBR-UHFFFAOYSA-N 0.000 description 1
- RBSDRIFVZMGRIX-UHFFFAOYSA-N CS(O)(=O)=O.Cc1nc2ccc(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound CS(O)(=O)=O.Cc1nc2ccc(F)cc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 RBSDRIFVZMGRIX-UHFFFAOYSA-N 0.000 description 1
- JKXSMMOLZBZWJJ-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(c(F)c2)C(F)(F)F)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(Cl)nc(Nc2ccc(c(F)c2)C(F)(F)F)n1 JKXSMMOLZBZWJJ-UHFFFAOYSA-N 0.000 description 1
- WUATVZPJYFNDCN-UHFFFAOYSA-N Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 WUATVZPJYFNDCN-UHFFFAOYSA-N 0.000 description 1
- NNEWHCMTXZZLJU-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC.COC2=CC=C(C=N2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N Chemical compound ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)CC.COC2=CC=C(C=N2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N NNEWHCMTXZZLJU-UHFFFAOYSA-N 0.000 description 1
- LVVZUCHDYUNTPB-UHFFFAOYSA-N ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)CC.ClC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N Chemical compound ClC1=CC=C(C=C1)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)CC.ClC=2C=C(C=CC2OC)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)C)N LVVZUCHDYUNTPB-UHFFFAOYSA-N 0.000 description 1
- ATLSBUFEIWWDSZ-UHFFFAOYSA-N ClC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)CC.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=C(C=C2)OC)F)N)C=CC=C1 Chemical compound ClC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)CC.C(C)C2=NC1=C(N2C2=CC(=NC(=N2)NC2=CC(=C(C=C2)OC)F)N)C=CC=C1 ATLSBUFEIWWDSZ-UHFFFAOYSA-N 0.000 description 1
- IPLOFMYOSBNZIA-UHFFFAOYSA-N FC(C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F)F Chemical compound FC(C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C(F)(F)F)N)C=C(C=C2)F)F IPLOFMYOSBNZIA-UHFFFAOYSA-N 0.000 description 1
- RMDCWCGMSSEDLD-UHFFFAOYSA-N FC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.ClC=2C=C(C=CC2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N Chemical compound FC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=C(C=C2)F)C.ClC=2C=C(C=CC2)C2(NC(=CC(=N2)N)N2C(=NC1=C2C=C(C=C1)F)C)N RMDCWCGMSSEDLD-UHFFFAOYSA-N 0.000 description 1
- FBUQJVNPTMIRJW-UHFFFAOYSA-N FC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.FC2(OC1=C(O2)C=CC(=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N)F Chemical compound FC=1C=C(C=CC1OC)NC1=NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C.FC2(OC1=C(O2)C=CC(=C1)C1(NC(=CC(=N1)N)N1C(=NC2=C1C=CC=C2)C)N)F FBUQJVNPTMIRJW-UHFFFAOYSA-N 0.000 description 1
- VGWOORPOWDKARZ-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)F)N)C1.NC1=NC(=NC(=C1)N1C(=NC2=C1C=C(C=C2)F)C)NC2=CC=C(C#N)C=C2 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)F)N)C1.NC1=NC(=NC(=C1)N1C(=NC2=C1C=C(C=C2)F)C)NC2=CC=C(C#N)C=C2 VGWOORPOWDKARZ-UHFFFAOYSA-N 0.000 description 1
- SNALIXTYWXQXAT-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)OC)N)C1.FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C1 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)OC)N)C1.FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC(=CC=C2)C)N)C1 SNALIXTYWXQXAT-UHFFFAOYSA-N 0.000 description 1
- ZLKFERQDWYHBGK-UHFFFAOYSA-N FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C1 Chemical compound FC=1C=CC2=C(N(C(=N2)C)C2=CC(=NC(=N2)NC2=CC=C(C=C2)C(F)(F)F)N)C1 ZLKFERQDWYHBGK-UHFFFAOYSA-N 0.000 description 1
- AJHWDYORKPTDRE-UHFFFAOYSA-N FC=1C=CC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC(=CC=C1)C)N Chemical compound FC=1C=CC=2N(C=1)C(=C(N=2)C)C1=CC(=NC(=N1)NC1=CC(=CC=C1)C)N AJHWDYORKPTDRE-UHFFFAOYSA-N 0.000 description 1
- SGHQFNHCCOBUKB-UHFFFAOYSA-N NC1=CC=NC(N)=[N+]1[O-] Chemical compound NC1=CC=NC(N)=[N+]1[O-] SGHQFNHCCOBUKB-UHFFFAOYSA-N 0.000 description 1
- PLVKGVGFEVQFHW-UHFFFAOYSA-N Nc1cc(nc(Nc2ccc(OC(F)F)cc2)n1)-n1c(nc2ccccc12)C1CC1 Chemical compound Nc1cc(nc(Nc2ccc(OC(F)F)cc2)n1)-n1c(nc2ccccc12)C1CC1 PLVKGVGFEVQFHW-UHFFFAOYSA-N 0.000 description 1
- URGBORRMLDCTDM-UHFFFAOYSA-N O1COC2=C1C=CC(=C2)NC2=NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC.C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=CC=C2 Chemical compound O1COC2=C1C=CC(=C2)NC2=NC(=CC(=N2)N)N2C(=NC1=C2C=CC=C1)CC.C(C)C1=NC2=C(N1C1=CC(=NC(=N1)NC1=CC=C(C=C1)C)N)C=CC=C2 URGBORRMLDCTDM-UHFFFAOYSA-N 0.000 description 1
- DJQMYWKOBNWPSN-UHFFFAOYSA-N OS(O)(=O)=O.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 Chemical compound OS(O)(=O)=O.Cc1nc2ccccc2n1-c1cc(N)nc(Nc2ccc(cc2)C(F)(F)F)n1 DJQMYWKOBNWPSN-UHFFFAOYSA-N 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- RWKSAOYDRMRQTD-UHFFFAOYSA-L disodium 6-(6-fluoro-2-methylbenzimidazol-1-yl)-4-N-phosphonato-2-N-[4-(trifluoromethyl)phenyl]pyrimidine-2,4-diamine Chemical compound [Na+].[Na+].Cc1nc2ccc(F)cc2n1-c1cc(NP([O-])([O-])=O)nc(Nc2ccc(cc2)C(F)(F)F)n1 RWKSAOYDRMRQTD-UHFFFAOYSA-L 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361872091P | 2013-08-30 | 2013-08-30 | |
| US61/872,091 | 2013-08-30 | ||
| PCT/US2013/071216 WO2015030847A1 (en) | 2013-08-30 | 2013-11-21 | Substituted pyrimidine bmi-1 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018234524A Division JP6728321B2 (ja) | 2013-08-30 | 2018-12-14 | 置換ピリミジンＢｍｉ−１阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016529292A JP2016529292A (ja) | 2016-09-23 |
| JP2016529292A5 true JP2016529292A5 (enExample) | 2017-01-05 |
| JP6524094B2 JP6524094B2 (ja) | 2019-06-05 |
Family
ID=52587180
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538906A Expired - Fee Related JP6524094B2 (ja) | 2013-08-30 | 2013-11-21 | 置換ピリミジンＢｍｉ−１阻害剤 |
| JP2018234524A Expired - Fee Related JP6728321B2 (ja) | 2013-08-30 | 2018-12-14 | 置換ピリミジンＢｍｉ−１阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018234524A Expired - Fee Related JP6728321B2 (ja) | 2013-08-30 | 2018-12-14 | 置換ピリミジンＢｍｉ−１阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10370371B2 (enExample) |
| EP (1) | EP3039015B1 (enExample) |
| JP (2) | JP6524094B2 (enExample) |
| KR (1) | KR102232595B1 (enExample) |
| CN (1) | CN105683166B (enExample) |
| AR (1) | AR093580A1 (enExample) |
| AU (2) | AU2013399092A1 (enExample) |
| CA (1) | CA2922657C (enExample) |
| CL (1) | CL2016000466A1 (enExample) |
| EA (1) | EA034866B1 (enExample) |
| IL (1) | IL244321B (enExample) |
| MX (1) | MX370588B (enExample) |
| NZ (2) | NZ718055A (enExample) |
| TW (1) | TWI692477B (enExample) |
| WO (1) | WO2015030847A1 (enExample) |
| ZA (1) | ZA201601697B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015030847A1 (en) * | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| GB201321736D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| ES2989326T3 (es) | 2015-10-21 | 2024-11-26 | Otsuka Pharma Co Ltd | Compuestos de benzolactama como inhibidores de la proteína cinasa |
| US10851082B2 (en) | 2015-10-28 | 2020-12-01 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) |
| WO2017125530A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New substituted cyanoindoline derivatives as nik inhibitors |
| US11001569B2 (en) | 2016-01-22 | 2021-05-11 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors |
| CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
| CN109641882B (zh) | 2016-06-30 | 2022-10-28 | 杨森制药有限公司 | 作为nik抑制剂的杂芳族衍生物 |
| ES2837157T3 (es) | 2016-06-30 | 2021-06-29 | Janssen Pharmaceutica Nv | Derivados de cianoindolina como inhibidores de NIK |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| EP3697777A1 (en) | 2017-10-19 | 2020-08-26 | eFFECTOR Therapeutics, Inc. | Benzimidazole-indole inhibitors of mnk1 and mnk2 |
| CR20200503A (es) | 2018-04-26 | 2020-12-17 | Pfizer | Inhibidores de cinasa dependientes de ciclina |
| EP3564235A1 (en) * | 2018-05-03 | 2019-11-06 | Northwestern University | Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2) |
| US11319302B2 (en) | 2018-06-07 | 2022-05-03 | The Regents Of The University Of Michigan | PRC1 inhibitors and methods of treatment therewith |
| AU2019340402B2 (en) | 2018-08-17 | 2025-04-03 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| AU2020227748A1 (en) * | 2019-02-28 | 2021-09-16 | Ptc Therapeutics, Inc. | Method for treating a multiple myeloma |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| WO2020224568A1 (en) | 2019-05-05 | 2020-11-12 | Qilu Regor Therapeutics Inc. | Cdk inhibitors |
| CN114269742B (zh) * | 2019-07-10 | 2024-07-16 | 常州千红生化制药股份有限公司 | 作为治疗剂的4-(咪唑并[1,2-a]吡啶-3-基)-N-(吡啶基)嘧啶-2-胺的衍生物 |
| AU2020318710B2 (en) * | 2019-07-24 | 2025-11-20 | Merck Patent Gmbh | 4-(imidazo[1,2-a]pyridin-3-yl) -pyrimidine derivatives |
| MX2022001940A (es) | 2019-08-14 | 2022-05-10 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2. |
| CN119930610A (zh) | 2019-10-11 | 2025-05-06 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| WO2023250439A1 (en) * | 2022-06-22 | 2023-12-28 | Tempest Therapeutics, Inc. | Trex1 inhibitors and uses thereof |
| TW202513069A (zh) | 2023-07-21 | 2025-04-01 | 美商冰洲石生物科技公司 | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH593266A5 (enExample) | 1973-09-20 | 1977-11-30 | Delalande Sa | |
| JPH07502496A (ja) | 1991-10-07 | 1995-03-16 | バイオゲン インコーポレイテッド | Ｃｄ２／ｌｆａ−３相互作用の阻害剤を用いる抗原提示細胞による皮膚障害の予防または治療の方法 |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| CN1102144C (zh) | 1994-08-13 | 2003-02-26 | 株式会社柳韩洋行 | 新的嘧啶衍生物及其制备方法 |
| IN188411B (enExample) * | 1997-03-27 | 2002-09-21 | Yuhan Corp | |
| KR100272471B1 (ko) * | 1998-11-17 | 2000-11-15 | 김선진 | 신규의 피리미딘 유도체 및 그의 제조방법 |
| DE60006541D1 (de) * | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
| GB9919778D0 (en) * | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| ATE396978T1 (de) | 1999-10-07 | 2008-06-15 | Amgen Inc | Triazin-kinase-hemmer |
| ES2254238T3 (es) * | 1999-10-27 | 2006-06-16 | Novartis Ag | Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico. |
| MXPA02007957A (es) | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
| HUP0300382A3 (en) | 2000-03-29 | 2006-11-28 | Cyclacel Ltd | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds |
| DK1318997T3 (da) | 2000-09-15 | 2006-09-25 | Vertex Pharma | Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer |
| DK1330452T3 (da) | 2000-09-20 | 2009-03-16 | Ortho Mcneil Janssen Pharm | Pyrazinderivater som modulatorer af tyrosinkinaser |
| US6716851B2 (en) | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| ES2316546T3 (es) | 2001-02-20 | 2009-04-16 | Astrazeneca Ab | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. |
| CA2439263C (en) | 2001-03-02 | 2012-10-23 | Frank Becker | Three hybrid assay system |
| US7196095B2 (en) | 2001-06-25 | 2007-03-27 | Merck & Co., Inc. | (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds |
| WO2003004492A1 (en) | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| US7109204B2 (en) | 2001-08-01 | 2006-09-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| EP1533304B1 (en) | 2002-06-28 | 2009-11-04 | Nippon Shinyaku Co., Ltd. | Amide derivative |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| US7060850B2 (en) | 2002-07-11 | 2006-06-13 | Fluorous Technologies Incorporated | Fluorous tagging and scavenging reactants and methods of synthesis and use thereof |
| US20040110821A1 (en) | 2002-08-07 | 2004-06-10 | Konkel Michael J. | GAL3 receptor antagonists for the treatment of affective disorders |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| US7582630B2 (en) | 2002-10-15 | 2009-09-01 | Smithkline Beecham Corporation | Pyradazine compounds as GSK-3 inhibitors |
| US7169781B2 (en) | 2003-10-17 | 2007-01-30 | Hoffmann-La Roche Inc. | Imidazole derivatives and their use as pharmaceutical agents |
| DK1704145T3 (da) | 2004-01-12 | 2012-09-24 | Ym Biosciences Australia Pty | Selektive kinaseinhibitorer |
| WO2005076854A2 (en) * | 2004-02-04 | 2005-08-25 | Smithkline Beecham Corporation | Pyrimidinone compounds useful as kinase inhibitors |
| NZ584499A (en) | 2004-03-30 | 2011-08-26 | Vertex Pharma | Azaindoles Useful as Inhibitors of Jak and Other Protein Kinases |
| JP2006045119A (ja) | 2004-08-04 | 2006-02-16 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| WO2006050076A1 (en) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| KR100917511B1 (ko) | 2005-02-28 | 2009-09-16 | 니뽄 다바코 산교 가부시키가이샤 | Ｓｙｋ 저해 활성을 갖는 신규한 아미노피리딘 화합물 |
| GT200600105A (es) | 2005-03-10 | 2007-02-14 | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos. | |
| EP2044051B1 (en) | 2006-06-22 | 2010-01-27 | BIOVITRUM AB (publ) | Pyridine and pyrazine derivatives as mnk kinase inhibitors |
| WO2008040753A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
| CN101516873A (zh) | 2006-10-03 | 2009-08-26 | 神经研究公司 | 用作钾通道调节剂的吲唑基衍生物 |
| MX2009004019A (es) | 2006-10-19 | 2009-06-19 | Signal Pharm Llc | Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa. |
| AU2007336933A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections |
| CL2008000197A1 (es) | 2007-01-26 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. |
| AU2008215948A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperazine derivatives for treatment of AD and related conditions |
| TW200846344A (en) | 2007-04-25 | 2008-12-01 | Astrazeneca Ab | Chemical compounds |
| GB0714573D0 (en) | 2007-07-26 | 2007-09-05 | Imp Innovations Ltd | Marker gene |
| US8415358B2 (en) | 2007-09-17 | 2013-04-09 | Neurosearch A/S | Pyrazine derivatives and their use as potassium channel modulators |
| ES2569528T3 (es) | 2007-11-16 | 2016-05-11 | Incyte Holdings Corporation | 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus |
| CA2707989A1 (en) | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| DE102008005493A1 (de) * | 2008-01-22 | 2009-07-23 | Merck Patent Gmbh | 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate |
| GB0801416D0 (en) * | 2008-01-25 | 2008-03-05 | Piramed Ltd | Pharmaceutical compounds |
| JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ， インコーポレイテッド | タンパク質キナーゼの阻害剤 |
| ES2605815T3 (es) * | 2008-07-01 | 2017-03-16 | Ptc Therapeutics, Inc. | Moduladores de la expresión de la proteína Bmi-1 |
| JP2012501308A (ja) | 2008-09-02 | 2012-01-19 | ノイロサーチ アクティーゼルスカブ | ピラゾリルピリミジン誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| WO2010061903A1 (ja) | 2008-11-27 | 2010-06-03 | 塩野義製薬株式会社 | Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体 |
| KR20110120286A (ko) | 2009-02-12 | 2011-11-03 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로환 유도체 |
| US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| US8536180B2 (en) | 2009-05-27 | 2013-09-17 | Abbvie Inc. | Pyrimidine inhibitors of kinase activity |
| WO2010144416A1 (en) * | 2009-06-08 | 2010-12-16 | Gaeta Federico C A | SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY |
| GEAP202213376A (en) | 2009-06-17 | 2022-02-25 | Vertex Pharmaceuticals Incorporated Us | Inhibitors of influenza viruses replication |
| US8486939B2 (en) | 2009-07-07 | 2013-07-16 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| CA2767089A1 (en) | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyridine inhibitors of kinases |
| JP5415176B2 (ja) | 2009-08-06 | 2014-02-12 | 株式会社マキタ | スイッチ |
| CN102812022B (zh) | 2010-01-12 | 2016-02-03 | Ab科学有限公司 | 噻唑和噁唑激酶抑制剂 |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| ES2365960B1 (es) | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | Nuevos antagonistas de los receptores de adenosina. |
| CN103025725B (zh) | 2010-08-10 | 2015-09-16 | 安斯泰来制药有限公司 | 杂环化合物 |
| SI2616465T1 (sl) | 2010-09-13 | 2016-02-29 | Novartis Ag | Triazin-oksadiazoli |
| WO2012050884A2 (en) | 2010-09-28 | 2012-04-19 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| MX2013006467A (es) | 2010-12-09 | 2013-10-01 | Amgen Inc | Compuestos biciclicos como inhibidores pim. |
| DK2678332T3 (en) | 2011-02-25 | 2016-08-15 | Yuhan Corp | Diaminopyrimidine derivatives and process for their preparation |
| AU2012280725B2 (en) | 2011-07-07 | 2017-02-02 | Merck Patent Gmbh | Substituted azaheterocycles for the treatment of cancer |
| EA035349B1 (ru) | 2012-11-21 | 2020-05-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| WO2015030847A1 (en) * | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
-
2013
- 2013-11-21 WO PCT/US2013/071216 patent/WO2015030847A1/en not_active Ceased
- 2013-11-21 EA EA201690502A patent/EA034866B1/ru not_active IP Right Cessation
- 2013-11-21 AR ARP130104301A patent/AR093580A1/es active IP Right Grant
- 2013-11-21 KR KR1020167008197A patent/KR102232595B1/ko not_active Expired - Fee Related
- 2013-11-21 NZ NZ718055A patent/NZ718055A/en not_active IP Right Cessation
- 2013-11-21 MX MX2016002642A patent/MX370588B/es active IP Right Grant
- 2013-11-21 AU AU2013399092A patent/AU2013399092A1/en not_active Abandoned
- 2013-11-21 NZ NZ748260A patent/NZ748260A/en not_active IP Right Cessation
- 2013-11-21 CN CN201380080643.5A patent/CN105683166B/zh not_active Expired - Fee Related
- 2013-11-21 US US14/914,909 patent/US10370371B2/en active Active
- 2013-11-21 CA CA2922657A patent/CA2922657C/en active Active
- 2013-11-21 EP EP13892399.0A patent/EP3039015B1/en not_active Not-in-force
- 2013-11-21 TW TW102142556A patent/TWI692477B/zh not_active IP Right Cessation
- 2013-11-21 JP JP2016538906A patent/JP6524094B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-28 IL IL244321A patent/IL244321B/en active IP Right Grant
- 2016-02-29 CL CL2016000466A patent/CL2016000466A1/es unknown
- 2016-03-11 ZA ZA2016/01697A patent/ZA201601697B/en unknown
-
2018
- 2018-11-27 AU AU2018271277A patent/AU2018271277B2/en not_active Ceased
- 2018-12-14 JP JP2018234524A patent/JP6728321B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016529292A5 (enExample) | ||
| JP2016504290A5 (enExample) | ||
| US11135201B2 (en) | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | |
| US10421761B2 (en) | Compounds for kinase modulation, and indications therefor | |
| JP2025134754A (ja) | Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類 | |
| RU2020112759A (ru) | Гетероциклические соединения в качестве ингибиторов PAD | |
| JP2016537384A5 (enExample) | ||
| JP2015511224A5 (enExample) | ||
| JP2016522232A5 (enExample) | ||
| EP4237086A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2019503337A5 (enExample) | ||
| JPWO2020052631A5 (enExample) | ||
| WO2023114225A1 (en) | Pharmaceutical combination comprising abemaciclib and a pi3k and/or a mtor inhibitor for the treatment of mantle cell lymphoma | |
| Veerasamy | Mitogen-Activating Protein Kinases (MAPK) Inhibitors for Cancer Treatment | |
| RU2021107655A (ru) | Соединения триазоло-пиримидина и их применение |